| | |
Placebo
|
MFGM
|
ANOVA (G × T)
|
|---|
|
P
-value
|
|---|
|
Aspartate aminotransferase, IU/L
|
baseline
|
24.5 ± 1.82
|
22.1 ± 0.98
|
0.591
|
|
5 weeks
|
25.1 ± 2.53
|
22.3 ± 0.77
|
|
10 weeks
|
24.1 ± 1.52
|
22.7 ± 1.06
|
|
Δ 10 weeks (%)a
|
1.0 ± 5.3
|
5.1 ± 5.0
|
|
Alanine aminotransferase, IU/L
|
baseline
|
25.1 ± 4.33
|
20.1 ± 2.02
|
0.674
|
|
5 weeks
|
23.7 ± 4.49
|
18.8 ± 2.03
|
|
10 weeks
|
22.9 ± 2.79
|
19.7 ± 2.38
|
|
Δ 10 weeks (%)a
|
- 0.1 ± 7.3
|
1.7 ± 6.6
|
|
Glucose, mg/dl
|
baseline
|
93.3 ± 2.01
|
90.4 ± 2.13
|
0.827
|
|
5 weeks
|
93.4 ± 2.81
|
90.5 ± 2.21
|
|
10 weeks
|
90.4 ± 2.22
|
88.6 ± 1.96
|
|
Δ 10 weeks (%)a
|
- 3.0 ± 1.8
|
- 1.8 ± 1.2
|
|
Triglyceride, mg/dl
|
baseline
|
132 ± 12.7
|
104 ± 9.4
|
0.536
|
|
5 weeks
|
103 ± 10.2
|
89 ± 6.4
|
|
10 weeks
|
109 ± 10.9
|
95 ± 8.6
|
|
Δ 10 weeks (%)a
|
- 12.3 ± 6.7
|
- 2.6 ± 8.9
|
|
Total cholesterol, mg/dl
|
baseline
|
206 ± 9.2
|
219 ± 9.8
|
0.190
|
|
5 weeks
|
210 ± 10.8
|
221 ± 9.8
|
|
10 weeks
|
211 ± 9.9
|
212 ± 7.5
|
|
Δ 10 weeks (%)a
|
2.9 ± 2.3
|
- 2.0 ± 2.0
|
- MFGM, milk fat globule membrane; ANOVA, analysis of variance.
- Values are means ± SEM of 16 (placebo group [women, n = 7; men, n = 9]) and 19 (MFGM group [women, n = 11; men, n = 8]) subjects.
-
aThe value is the percentage change from the baseline to 10 weeks. Repeated-measures ANOVA for the group-by-time interaction (G × T) during the interventional period.
